Timothy Yap, MBBS, PhD, FRCP, University of Texas MD Anderson Cancer Center, Houston, TX, discusses latest advances in the use of PARP inhibitors and other DNA damage response inhibitors in the treatment of breast cancer, including the role of cancer genome sequencing to identify novel targets. This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.